Phase Ib/II Trial of Gemcitabine, Cisplatin, and Lenalidomide as First-Line Therapy in Patients With Metastatic Urothelial Carcinoma

BACKGROUND. Outcomes with current chemotherapy in metastatic urothelial carcinoma (MUC) remain poor. Lenalidomide, an antiangiogenic and immunomodulatory agent, enhances the effects of chemotherapy in preclinical studies. In this phase Ib/II study, we sought to determine a tolerable dose of lenalido...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Agarwal, Neeraj, Apolo, Andrea B., Tsao, Che-Kai, Lee, Karen M., Godbold, James H., Soto, Rothschild, Poole, Austin, Gimpel-Tetra, Kiev, Lowe, Nancy, Oh, William K., Galsky, Matthew D.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: AlphaMed Press 2014
Aiheet:
Clinical Trial Results
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4153455/
https://ncbi.nlm.nih.gov/pubmed/25052451
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0153
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia